
Sono1 mg
ACME Laboratories Ltd.
Eszopiclone is a non-benzodiazepine sedative-hypnotic (a "Z-drug") indicated for: Treatment of insomnia (FDA-approved and more.
Eszopiclone is a non-benzodiazepine sedative-hypnotic (a "Z-drug") indicated for:
Eszopiclone is not approved for use in pediatric patients; studies in adolescents did not demonstrate efficacy (see Use in Special Populations).
Eszopiclone should be taken immediately before bedtime, only when the patient is able to devote a full night (at least 7-8 hours) to sleep before needing to be active again. It may be taken with or without food, but taking it with or soon after a heavy or high-fat meal may slow onset of action.
| Population / Indication | Recommended Dose |
|---|---|
| Adults (general, insomnia) | Starting dose 1 mg at bedtime; may be increased to 2 mg or 3 mg based on response and tolerability. Maximum recommended dose: 3 mg once daily. |
| Elderly patients (primarily sleep-onset difficulty) | 1 mg at bedtime; may be increased to 2 mg if needed. |
| Elderly patients (primarily sleep-maintenance difficulty) | 1 mg at bedtime (do not exceed 2 mg). |
| Hepatic impairment | Starting dose 1 mg; do not exceed 2 mg. |
| With concomitant strong CYP3A4 inhibitors | Starting dose 1 mg; do not exceed 2 mg (see Interactions). |
| Renal impairment (mild-moderate) | No dose adjustment generally required; use standard adult dosing with caution. |
Dose escalation should be individualized to the lowest effective dose. Eszopiclone is generally intended for short-term or intermittent use with periodic reassessment if used longer-term; it should not be combined with alcohol or other CNS depressants (see Precautions and Interactions).
The most common side effect of Eszopiclone is an unpleasant (metallic/bitter) taste, reported in a substantial proportion of patients, particularly at higher doses. Other side effects include:
Serious risks (see Precautions and Warnings for full detail): complex sleep behaviors (e.g., sleep-walking, sleep-driving, preparing and eating food, or making phone calls while not fully awake, with amnesia for the event), next-day impairment of driving/mental alertness, and dependence/withdrawal symptoms with abrupt discontinuation after prolonged use.
Eszopiclone is contraindicated in patients with known hypersensitivity to Eszopiclone or any component of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.